drugset / Trial / NCT06067698
Alpha Lipoic Acid in Ulcerative Colitis
RandomizedParallel-groupSingle-blindTreatment
Summary
This study aims at evaluating the efficacy and safety of alpha-lipoic acid as adjuvant therapy to mesalamine in patients with mild to moderate ulcerative colitis due to its effect as anti-oxidant and anti-inflammatory drug which can help to improve disease.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2025-04-01
- Completion
- 2025-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | alpha-lipoic acid | Small molecule | 600 mg | — |
| Comparator | Mesalamine | Small molecule | 1000 mg | — |